<!DOCTYPE html>



<html lang="en">



	<meta charset="UTF-8">

	<meta name="viewport" content="width=device-width, initial-scale=1.0">

	<style>


    .node {

        stroke: #fff;

        stroke-width: 2px;

    }

    

    .link {

        stroke: #777;

        stroke-width: 2px;

    }



</style>

<body>

<a href="https://riskrunners.com">Home</a><br>




<a href="#risk_factors">Jump to Risk Factors</a><br>



<a href="#industry">Jump to Industries</a><br>


<a href="#exposure">Jump to Exposures</a><br>


<a href="#event_code">Jump to Event Codes</a><br>


<a href="#wiki">Jump to Wiki Summary</a><br><br>


    <script src="https://d3js.org/d3.v3.min.js"></script>

    <script>


// set a width and height for our SVG

var width = 3000,


    height = 3000;

    
// setup links

var links =     [
{source: "START_HERE", target: "14: Prochieve ", fill: "#96c8a2"},
{source: "14: Prochieve ", target: "14: worldwide license", fill: "#96c8a2"},
{source: "14: worldwide license", target: "14: progesterone", fill: "#96c8a2"},
{source: "14: Prochieve ", target: "59: addition investors may become concerned about", fill: "#6da"},
{source: "59: addition investors may become concerned about", target: "59: common stock", fill: "#6da"},
{source: "59: addition investors may become concerned about", target: "70: competitive position", fill: "#86608e"},
{source: "70: competitive position", target: "70: partially dependent on", fill: "#86608e"},
{source: "70: partially dependent on", target: "70: proprietary position", fill: "#86608e"},
{source: "70: proprietary position", target: "70: technology products", fill: "#86608e"},
{source: "70: technology products", target: "70: candidates", fill: "#86608e"},
{source: "70: competitive position", target: "91: every aspect", fill: "#48d1cc"},
{source: "91: every aspect", target: "91: development manufacture", fill: "#48d1cc"},
{source: "91: development manufacture", target: "91: commercialization", fill: "#48d1cc"},
{source: "91: commercialization", target: "91: approved pharmaceutical products", fill: "#48d1cc"},
{source: "91: approved pharmaceutical products", target: "91: timeconsuming", fill: "#48d1cc"},
{source: "91: timeconsuming", target: "91: regulation by various governmental entities", fill: "#48d1cc"},
{source: "91: regulation by various governmental entities", target: "91: regulatory", fill: "#48d1cc"},
{source: "91: regulatory", target: "91: manufactured", fill: "#48d1cc"},
{source: "91: manufactured", target: "91: distributed", fill: "#48d1cc"},
{source: "91: every aspect", target: "101: candidates", fill: "#f5deb3"},
{source: "101: candidates", target: "101: development may fail", fill: "#f5deb3"},
{source: "101: development may fail", target: "101: trials may show", fill: "#f5deb3"},
{source: "101: trials may show", target: "101: product candidates", fill: "#f5deb3"},
{source: "101: product candidates", target: "101: ineffective", fill: "#f5deb3"},
{source: "101: ineffective", target: "101: candidates may fail", fill: "#f5deb3"},
{source: "101: candidates may fail", target: "101: regulatory approvals", fill: "#f5deb3"},
{source: "101: regulatory approvals", target: "101: Manufacturing ", fill: "#f5deb3"},
{source: "101: Manufacturing ", target: "101: factors may", fill: "#f5deb3"},
{source: "101: factors may", target: "101: proprietary", fill: "#f5deb3"},
{source: "101: proprietary", target: "101: competing products", fill: "#f5deb3"},
{source: "101: competing products", target: "101: technologies may prevent", fill: "#f5deb3"},
{source: "101: technologies may prevent", target: "101: product candidates from", fill: "#f5deb3"},
{source: "101: product candidates from", target: "101: effectively", fill: "#f5deb3"},
{source: "101: effectively", target: "101: commercialized", fill: "#f5deb3"},
{source: "101: candidates", target: "140: dependent on", fill: "#0095b6"},
{source: "140: dependent on", target: "140: principal supplier", fill: "#0095b6"},
{source: "140: principal supplier", target: "140: which could impair", fill: "#0095b6"},
{source: "140: which could impair", target: "140: manufacture", fill: "#0095b6"},
{source: "140: dependent on", target: "176: Board of Directors ", fill: "#da1d81"},
{source: "176: Board of Directors ", target: "176: authorized shares", fill: "#da1d81"},
{source: "176: authorized shares", target: "176: participating", fill: "#da1d81"},
{source: "176: participating", target: "176: connection with", fill: "#da1d81"},
{source: "176: connection with", target: "176: stockholder rights", fill: "#da1d81"},
{source: "176: stockholder rights", target: "176: issued rights", fill: "#da1d81"},
{source: "176: issued rights", target: "176: purchase series", fill: "#da1d81"},
{source: "176: purchase series", target: "176: convertible preferred stock", fill: "#da1d81"},
{source: "176: convertible preferred stock", target: "176: common stock", fill: "#da1d81"},
{source: "176: Board of Directors ", target: "START_HERE", fill: "#da1d81"}]; 
    // create empty nodes array
    var nodes = {};
	var colorFill = [];
	
    // compute nodes from links data
    links.forEach(function(link) {
        link.source = nodes[link.source] ||
            (nodes[link.source] = {name: link.source});
        link.target = nodes[link.target] ||
            (nodes[link.target] = {name: link.target});
		colorFill.push({name: link.source.name, fill: link.fill });
		colorFill.push({name: link.target.name, fill: link.fill });
    });
	
	console.log(colorFill);


    // add a SVG to the body for our viz
    var svg=d3.select('body').append('svg')
        .attr("viewBox", "0 0 " + width + " " + height );

    // use the force
    var force = d3.layout.force()
		.charge(-5000)
		.gravity(0.3)
        .size([width, height])
        .nodes(d3.values(nodes))
        .links(links)
        .on("tick", tick)
        .linkDistance(200)
        .start();

    // add links
    var link = svg.selectAll('.link')
        .data(links)
        .enter().append('line')
        .attr('class', 'link'); 

    // add nodes
    var node = svg.selectAll('.node')
        .data(force.nodes())
        .enter().append('circle')
        .attr('class', 'node')
        .attr('r', width * 0.0035)
		.style("fill", function(d) {
									for (var i = 0; i < colorFill.length; i++) {
										//console.log(d.name);
										if(colorFill[i].name == d.name){
											console.log(colorFill[i].fill);
											return colorFill[i].fill;
										}
									} return "#555";
									
									});
	var label = svg.selectAll(null)
		.data(force.nodes())
		.enter()
		.append("text")
		.text(function (d) { return d.name; })
		.style("text-anchor", "middle")
		.style("fill", "#555")
		.style("font-family", "Arial")
		.style("font-size", 34);


    // what to do 
    function tick(e) {
        
        node.attr('cx', function(d) { return d.x = Math.max(6, Math.min(width - 6, d.x)); })
            .attr('cy', function(d) { return d.y = Math.max(6, Math.min(height - 6, d.y)); })
            .call(force.drag);
            
        link.attr('x1', function(d) { return d.source.x; })
            .attr('y1', function(d) { return d.source.y; })
            .attr('x2', function(d) { return d.target.x; })
            .attr('y2', function(d) { return d.target.y; });
		
		label.attr("x", function(d){ return d.x; })
             .attr("y", function (d) {return d.y - 10; });
        
    }
    
</script><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='industry'>Industries</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Health Care Facilities</td>
    </tr>
    <tr>
      <td>Health Care Supplies</td>
    </tr>
    <tr>
      <td>Health Care</td>
    </tr>
    <tr>
      <td>Health Care Equipment and Services</td>
    </tr>
    <tr>
      <td>Managed Health Care</td>
    </tr>
    <tr>
      <td>Health Care Distribution and Services</td>
    </tr>
    <tr>
      <td>Investment Banking and Brokerage</td>
    </tr>
    <tr>
      <td>Technology Hardware Storage and Peripherals</td>
    </tr>
    <tr>
      <td>Information Technology</td>
    </tr>
    <tr>
      <td>Technology Hardware and Equipment</td>
    </tr>
    <tr>
      <td>Application Software</td>
    </tr>
    <tr>
      <td>Independent Power Producers and Energy Traders</td>
    </tr>
    <tr>
      <td>Automobile Manufacturers</td>
    </tr>
    <tr>
      <td>Motorcycle Manufacturers</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='exposure'>Exposures</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Military</td>
    </tr>
    <tr>
      <td>Express intent</td>
    </tr>
    <tr>
      <td>Regime</td>
    </tr>
    <tr>
      <td>Ease</td>
    </tr>
    <tr>
      <td>Political reform</td>
    </tr>
    <tr>
      <td>Cooperate</td>
    </tr>
    <tr>
      <td>Crime</td>
    </tr>
    <tr>
      <td>Provide</td>
    </tr>
    <tr>
      <td>Rights</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='event_code'>Event Codes</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>Accident</td>
    </tr>
    <tr>
      <td>Solicit support</td>
    </tr>
    <tr>
      <td>Yield to order</td>
    </tr>
    <tr>
      <td>Riot</td>
    </tr>
    <tr>
      <td>Endorse</td>
    </tr>
    <tr>
      <td>Military blockade</td>
    </tr>
    <tr>
      <td>Agree</td>
    </tr>
    <tr>
      <td>Release or return</td>
    </tr>
    <tr>
      <td>Sports contest</td>
    </tr>
    <tr>
      <td>Complain</td>
    </tr>
    <tr>
      <td>Force</td>
    </tr>
    <tr>
      <td>Request</td>
    </tr>
    <tr>
      <td>Demand</td>
    </tr>
    <tr>
      <td>Comment</td>
    </tr>
    <tr>
      <td>Promise</td>
    </tr>
    <tr>
      <td>Yield</td>
    </tr>
    <tr>
      <td>Adjust</td>
    </tr>
    <tr>
      <td>Acknowledge responsibility</td>
    </tr>
    <tr>
      <td>Seize</td>
    </tr>
    <tr>
      <td>Warn</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='wiki'>Wiki</th>
      <th>Wiki Summary</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Spermicide">Spermicide</a></td>
      <td>Spermidine is a polyamine compound (C7H19N3) found in ribosomes and living tissues and having various metabolic functions within organisms. It was originally isolated from semen.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Bioidentical_hormone_replacement_therapy">Bioidentical hormone replacement therapy</a></td>
      <td>Bioidentical hormone replacement therapy (BHRT), also known as bioidentical hormone therapy or natural hormone therapy, is the use of hormones that are identical on a molecular level with endogenous hormones in hormone replacement therapy. It may also be combined with blood and saliva testing of hormone levels, and the use of pharmacy compounding to obtain hormones in an effort to reach a targeted level of hormones in the body.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock">Common stock</a></td>
      <td>Common stock is a form of corporate equity ownership, a type of security. The terms voting share and ordinary share are also used frequently outside of the United States.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Common_stock_dividend">Common stock dividend</a></td>
      <td>A common stock dividend is the dividend paid to common stock owners from the profits of the company.  Like other dividends, the payout is in the form of either cash or stock.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Preferred_stock">Preferred stock</a></td>
      <td>Preferred stock (also called preferred shares, preference shares, or simply preferreds) is a component of share capital that may have any combination of features not possessed by common stock, including properties of both an equity and a debt instrument, and is generally considered a hybrid instrument. Preferred stocks are senior (i.e., higher ranking) to common stock but subordinate to bonds in terms of claim (or rights to their share of the assets of the company, given that such assets are payable to the returnee stock bond) and may have priority over common stock (ordinary shares) in the payment of dividends and upon liquidation.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Matthiola_incana">Matthiola incana</a></td>
      <td>Matthiola incana is a species of flowering plant in the cabbage family Brassicaceae. Common names include Brompton stock, common stock, hoary stock, ten-week stock, and gilly-flower.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Consolidation_(business)">Consolidation (business)</a></td>
      <td>In business, consolidation or amalgamation is the merger and acquisition of many smaller companies into a few much larger ones. In the context of financial accounting, consolidation refers to the aggregation of financial statements of a group company as consolidated financial statements.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/New_York_Stock_Exchange">New York Stock Exchange</a></td>
      <td>The New York Stock Exchange (NYSE, nicknamed "The Big Board") is an American stock exchange in the Financial District of Lower Manhattan in New York City. It is by far the world's largest stock exchange by market capitalization of its listed companies at US$30.1 trillion as of February 2018.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Treasury_stock">Treasury stock</a></td>
      <td>A treasury stock or reacquired stock is stock which is bought back by the issuing company, reducing the amount of outstanding stock on the open market ("open market" including insiders' holdings). \nStock repurchases are used as a tax efficient method to put cash into shareholders' hands, rather than paying dividends, in jurisdictions that treat capital gains more favorably.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Convertible_bond">Convertible bond</a></td>
      <td>In finance, a convertible bond or  convertible note or convertible debt (or a convertible debenture if it has a maturity of greater than 10 years) is a type of bond that the holder can convert into a specified number of shares of common stock in the issuing company or cash of equal value.  It is a hybrid security with debt- and equity-like features.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidate">Candidate</a></td>
      <td>A candidate, or nominee, is the prospective recipient of an award or honor, or a person seeking or being considered for some kind of position; for example:\n\nto be elected to an office — in this case a candidate selection procedure occurs.\nto receive membership in a  group"Nomination" is part of the process of selecting a candidate for either election to an office by a political party, or the bestowing of an honor or award.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Write-in_candidate">Write-in candidate</a></td>
      <td>A write-in candidate is a candidate whose name does not appear on the ballot but seeks election by asking voters to cast a vote for the candidate by physically writing in the person's name on the ballot. Depending on electoral law it may be possible to win an election by winning a sufficient number of such write-in votes, which count equally as if the person was formally listed on the ballot.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament">Candidates Tournament</a></td>
      <td>The Candidates Tournament (or in some periods Candidates Matches) is a chess tournament organized by FIDE, chess's international governing body, since 1950, as the final contest to determine the challenger for the World Chess Championship. The winner of the Candidates earns the right to a match for the World Championship against the incumbent World Champion.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Perennial_candidate">Perennial candidate</a></td>
      <td>A perennial candidate is a political candidate who frequently runs for elected office and rarely, if ever, wins. Perennial candidates' existence lies in the fact that in some countries, there are no laws that limit a number of times a person can run for office, or laws that impose a non-negligible financial penalty on registering to run for election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_Tournament_2022">Candidates Tournament 2022</a></td>
      <td>The 2022 Candidates Tournament is an upcoming eight-player chess tournament, to decide the challenger for the World Chess Championship 2023. The tournament is scheduled to take place at the Palace of Santoña in Madrid, Spain from June 16 to July 5, 2022, with the World Championship to follow in early 2023.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/2022_Lebanese_general_election">2022 Lebanese general election</a></td>
      <td>General elections were held in Lebanon on 15 May 2022. The country has for several years been the subject of chronic political instability as well as a serious economic crisis aggravated by the 2020 explosions that hit the Port of Beirut and faced large-scale demonstrations against the political class.Hezbollah and their allies lost their parliamentary majority but still won the Parliament speaker election.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Candidates_in_the_2022_Philippine_Senate_election">Candidates in the 2022 Philippine Senate election</a></td>
      <td>This is a list of candidates in the 2022 Philippine Senate election.\n\n\n== Official candidates ==\nThe Commission on Elections has published a final list of accepted candidates which are now included in the printed ballots.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Grasshopper_Manufacture">Grasshopper Manufacture</a></td>
      <td>Grasshopper Manufacture Inc. (株式会社グラスホッパー・マニファクチュア, Kabushiki Gaisha Gurasuhoppā Manifakuchua) is a Japanese video game developer founded on March 30, 1998 by Goichi Suda.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacturing">Manufacturing</a></td>
      <td>Manufacturing is the creation or production of goods with the help of equipment, labor, machines, tools, and chemical or biological processing or formulation. It is the essence of secondary sector of the economy.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Automotive_industry">Automotive industry</a></td>
      <td>The automotive industry comprises a wide range of companies and organizations involved in the design, development, manufacturing, marketing, and selling of motor vehicles. It is one of the world's largest industries by revenue (from 16 % such as in France up to 40 % to countries like Slovakia).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulation">Regulation</a></td>
      <td>Regulation is the management of complex systems according to a set of rules and trends. In systems theory, these types of rules exist in various fields of biology and society, but the term has slightly different meanings according to context.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_agency">Regulatory agency</a></td>
      <td>A regulatory agency (regulatory body, regulator) or independent agency (independent regulatory agency) is a government authority that is responsible for exercising autonomous dominion over some area of human activity in a licensing and regulating capacity.\nThese are customarily set up to strengthen safety and standards, and/or to protect consumers in markets where there is a lack of effective competition.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_state">Regulatory state</a></td>
      <td>The term regulatory state refers to the expansion in the use of rulemaking, monitoring and enforcement techniques and institutions by the state and to a parallel change in the way its positive or negative functions in society are being carried out. The expansion of the state nowadays is generally via regulation and less via taxing and spending.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_capture">Regulatory capture</a></td>
      <td>In politics, regulatory capture (also agency capture and client politics) is a form of corruption of authority that occurs when a political entity, policymaker, or regulator is co-opted to serve the commercial, ideological, or political interests of a minor constituency, such as a particular geographic area, industry, profession, or ideological group.When regulatory capture occurs, a special interest is prioritized over the general interests of the public, leading to a net loss for society. The theory of client politics is related to that of rent-seeking and political failure; client politics "occurs when most or all of the benefits of a program go to some single, reasonably small interest (e.g., industry, profession, or locality) but most or all of the costs will be borne by a large number of people (for example, all taxpayers)".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sequence">Regulatory sequence</a></td>
      <td>A regulatory sequence is a segment of a nucleic acid molecule which is capable of increasing or decreasing the expression of specific genes within an organism. Regulation of gene expression is an essential feature of all living organisms and viruses.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_T_cell">Regulatory T cell</a></td>
      <td>The regulatory T cells (Tregs  or Treg cells), formerly known as suppressor T cells, are a subpopulation of T cells that modulate the immune system, maintain tolerance to self-antigens, and prevent autoimmune disease. Treg cells are immunosuppressive and generally suppress or downregulate induction and proliferation of effector T cells.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_sign">Regulatory sign</a></td>
      <td>A regulatory sign is used to indicate or reinforce traffic laws, regulations or requirements which apply either at all times or at specified times or places upon a street or highway, the disregard of which may constitute a violation, or a sign in general that regulates public behavior in places open to the public.  The FHWA defines regulatory sign as "a sign that gives notice to road users of traffic laws or regulations".</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Regulatory_focus_theory">Regulatory focus theory</a></td>
      <td>Regulatory focus theory (RFT) is a theory of goal pursuit: 444  formulated by Columbia University psychology professor and researcher E. Tory Higgins regarding people's perceptions in the decision making process. RFT examines the relationship between the motivation of a person and the way in which they go about achieving their goal.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gene_regulatory_network">Gene regulatory network</a></td>
      <td>A gene (or genetic) regulatory network (GRN) is a collection of molecular regulators that interact with each other and with other substances in the cell to govern the gene expression levels of mRNA and proteins which, in turn, determine the function of the cell. GRN also play a central role in morphogenesis, the creation of body structures, which in turn is central to evolutionary developmental biology (evo-devo).</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_d'horlogerie">Manufacture d'horlogerie</a></td>
      <td>Manufacture d'horlogerie (meaning "watchmaking manufacturer") is a French language term of horology that has also been adopted in the English language as a loanword. In horology, the term is usually encountered in its abbreviated form manufacture.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Gobelins_Manufactory">Gobelins Manufactory</a></td>
      <td>The Gobelins Manufactory (French: Manufacture des Gobelins) is a historic tapestry factory in Paris, France. It is located at 42 avenue des Gobelins, near Les Gobelins métro station in the 13th arrondissement of Paris.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Build-on-demand">Build-on-demand</a></td>
      <td>Build-on-demand or manufacturing on demand (MOD) refers to a manufacturing process where goods are produced only when or as they are required. This allows scalability and adjustable assemblies depending on the current needs of the part requestor or client.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Manufacture_nationale_de_Sèvres">Manufacture nationale de Sèvres</a></td>
      <td>The Manufacture nationale de Sèvres is one of the principal European porcelain factories. It is located in Sèvres, Hauts-de-Seine, France.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Computer-aided_manufacturing">Computer-aided manufacturing</a></td>
      <td>Computer-aided manufacturing (CAM) also known as computer-aided modeling or computer-aided machining is the use of software to control machine tools in the manufacturing of work pieces. This is not the only definition for CAM, but it is the most common; CAM may also refer to the use of a computer to assist in all operations of a manufacturing plant, including planning, management, transportation and storage.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Design_for_manufacturability">Design for manufacturability</a></td>
      <td>Design for manufacturability (also sometimes known as design for manufacturing or DFM) is the general engineering practice of designing products in such a way that they are easy to manufacture. The concept exists in almost all engineering disciplines, but the implementation differs widely depending on the manufacturing technology.</td>
    </tr>
    <tr>
      <td><a href="https://en.wikipedia.org/wiki/Shareholder_rights_plan">Shareholder rights plan</a></td>
      <td>A shareholder rights plan, colloquially known as a "poison pill", is a type of defensive tactic used by a corporation's board of directors against a takeover.\nIn the field of mergers and acquisitions, shareholder rights plans were devised in the early 1980s as a way to prevent takeover bids by taking away a shareholder's right to negotiate a price for the sale of shares directly.</td>
    </tr>
  </tbody>
</table><table border="1" class="dataframe">
  <thead>
    <tr style="text-align: right;">
      <th id='risk_factors'>Risk Factors</th>
    </tr>
  </thead>
  <tbody>
    <tr>
      <td>COLUMBIA LABORATORIES INC                              Item 1A Risk Factors       We have a history of losses and we <font color="blue">may continue</font> to <font color="blue">incur losses</font></td>
    </tr>
    <tr>
      <td>We have had a history of losses in <font color="blue">each fiscal year since</font> our founding</td>
    </tr>
    <tr>
      <td>For     the fiscal year ended <font color="blue">December </font>31, 2005, we had a net loss of dlra9dtta3 million</td>
    </tr>
    <tr>
      <td>If we and our partners are unable to <font color="blue">successfully market</font> our products, and     otherwise  increase  sales  of our products, and contain our operating     expenses, we may not have <font color="blue">sufficient funds</font> to <font color="blue">continue <font color="blue">operations</font> unless</font> we     are able to <font color="blue">raise <font color="blue"><font color="blue">additional</font> funds</font> from sales</font> of securities or otherwise</td>
    </tr>
    <tr>
      <td><font color="blue">Additional </font><font color="blue">financing may</font> not be available to us on acceptable terms, if at     all</td>
    </tr>
    <tr>
      <td>Our   business   is   heavily  <font color="blue">dependent</font>  on  the  continued  sale  of     Crinone^®,^ Replens^®,  RepHresh^®, Advantage-S^® and Striant^® by our     marketing  partners</td>
    </tr>
    <tr>
      <td>If <font color="blue">revenues from</font> these <font color="blue">partnered products fail</font> to     <font color="blue">increase as</font> anticipated, or <font color="blue"><font color="blue">materially</font> decline</font>, our <font color="blue">financial condition</font> and     results of <font color="blue"><font color="blue">operations</font> will</font> be <font color="blue"><font color="blue">materially</font> harmed</font></td>
    </tr>
    <tr>
      <td>Our operating results are heavily <font color="blue">dependent</font> on the revenues and royalties     derived  from  the sale of Crinone^® to Serono, the sale of Replens^®,     RepHresh^® and Advantage-S^® to Lil’ Drug Store Products, Inc</td>
    </tr>
    <tr>
      <td>We do not control the amount and timing of <font color="blue">marketing resources</font>     that our <font color="blue">partners devote</font> to our products</td>
    </tr>
    <tr>
      <td>If Serono fails to <font color="blue"><font color="blue">effective</font>ly</font>     market Crinone^®,^ Lil’ Drug Store Products fails to <font color="blue"><font color="blue"><font color="blue">effective</font>ly</font> market</font>     Replens^®, RepHresh^® and Advantage-S^® , or Ardana fails to <font color="blue"><font color="blue">effective</font>ly</font>     market Striant^® in Europe, this could have a material adverse effect on our     business, <font color="blue">financial condition</font> and results of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Our Marketing Agreement for Prochieve^® may be <font color="blue">terminated under certain</font>     <font color="blue">circumstances</font></td>
    </tr>
    <tr>
      <td>We market Prochieve^® under a June 2002 sublicense from Serono under the     <font color="blue">worldwide license</font> we granted to Serono for our <font color="blue">progesterone</font> gel</td>
    </tr>
    <tr>
      <td>Under the     terms of the license and sublicense, Serono markets Crinone^® <font color="blue">in the US </font>to     a defined list of <font color="blue">fertility</font> <font color="blue">specialists</font></td>
    </tr>
    <tr>
      <td>We are free to market Prochieve^®     to all other physicians in the US, including obstetricians, gynecologists     and  primary  care  physicians</td>
    </tr>
    <tr>
      <td>Serono  receives a 30prca royalty on all     Prochieve^® <font color="blue">sales dispensed</font> to patients of <font color="blue">physicians outside</font> its target     list  of  <font color="blue">fertility</font>  <font color="blue">specialists</font>  and an <font color="blue">additional</font> 40prca royalty on all     Prochieve^® <font color="blue">sales dispensed</font> to patients of <font color="blue">physicians on</font> Serono’s target     list of <font color="blue">fertility</font> <font color="blue">specialists</font></td>
    </tr>
    <tr>
      <td>17       _________________________________________________________________       Serono <font color="blue">may terminate</font> our <font color="blue">marketing <font color="blue">agreement</font></font> for Prochieve^® <font color="blue">by sending us</font>     written notice if (i) Prochieve^® is dispensed to patients of <font color="blue">physicians on</font>     Serono’s <font color="blue">target list</font> of <font color="blue">fertility</font> <font color="blue">specialists</font> in any <font color="blue">one calendar quarter at</font>     the  rate of 10prca or more of the amount of Crinone^® dispensed to those     patients, (ii) Serono <font color="blue">notifies us</font> in writing of its intent to terminate the     <font color="blue">marketing <font color="blue">agreement</font></font> and (iii) such rate continues to equal or exceed 10prca     during the <font color="blue">three <font color="blue">month period</font> following such</font> notice or a <font color="blue">subsequent three</font>     <font color="blue">month period</font></td>
    </tr>
    <tr>
      <td>If the <font color="blue">marketing <font color="blue">agreement</font></font> is terminated <font color="blue">and Serono </font>does not     market  Crinone^® to the physicians we call on, our <font color="blue"><font color="blue">profitability</font> with</font>     respect to Crinone^®/Prochieve^® may be <font color="blue">reduced <font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td><font color="blue">Healthcare </font>insurers and other payors may not pay for our products or may     <font color="blue">impose limits on <font color="blue">reimbursement</font></font></td>
    </tr>
    <tr>
      <td>Our ability to <font color="blue">commercialize</font> our <font color="blue"><font color="blue">prescription products</font> will depend</font>, in part,     on the extent to <font color="blue">which <font color="blue">reimbursement</font></font> for our products is <font color="blue">available from</font>     third-party  payors,  such as <font color="blue">health maintenance organizations</font>, health     insurers and other public and <font color="blue">private payors</font></td>
    </tr>
    <tr>
      <td>If we succeed in <font color="blue">bringing new</font>     <font color="blue">prescription products</font> to market, we cannot be assured that third-party     <font color="blue">payors will pay</font> for <font color="blue">such products</font>, or establish and maintain <font color="blue">price levels</font>     sufficient for <font color="blue">realization</font> of an <font color="blue"><font color="blue">appropriate</font> return on</font> our <font color="blue">investment</font> in     <font color="blue">product <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td>Many <font color="blue">health maintenance organizations</font> and other third-party payors use     formularies,  or lists of drugs for <font color="blue">which coverage</font> is <font color="blue">provided under</font> a     <font color="blue">healthcare benefit</font> plan, to control the costs of <font color="blue">prescription drugs</font></td>
    </tr>
    <tr>
      <td><font color="blue">Each     </font>payor that maintains a <font color="blue">drug formulary</font> makes its own <font color="blue">determination as</font> to     whether a <font color="blue">new drug will</font> be added to the formulary and <font color="blue">whether particular</font>     drugs in a <font color="blue">therapeutic</font> class will have <font color="blue"><font color="blue">preferred status</font> over</font> other drugs in     the same class</td>
    </tr>
    <tr>
      <td>This <font color="blue">determination often involves</font> an <font color="blue">assessment</font> of the     <font color="blue">clinical <font color="blue">appropriate</font>ness</font> of the drug and, in some cases, the cost of the     drug  in <font color="blue">comparison</font> to <font color="blue">alternative products</font></td>
    </tr>
    <tr>
      <td>Our current or our future     <font color="blue">products may</font> not be added to payors’ formularies, our <font color="blue">products may</font> not have     <font color="blue">preferred status</font> to <font color="blue">alternative therapies</font>, and <font color="blue">formulary decisions may</font> not     be conducted in a <font color="blue">timely manner</font></td>
    </tr>
    <tr>
      <td>Once <font color="blue"><font color="blue">reimbursement</font> at</font> an <font color="blue">agreed level</font> is     <font color="blue">approved by</font> a third-party payor, we may lose that <font color="blue"><font color="blue">reimbursement</font> entirely</font> or     we may lose the similar or <font color="blue">better <font color="blue">reimbursement</font></font> we receive compared to     <font color="blue">competitive products</font></td>
    </tr>
    <tr>
      <td>As <font color="blue">reimbursement</font> is often approved for a period of     time, this risk is <font color="blue">greater at</font> the end of the time period, if any, for which     the <font color="blue">reimbursement</font> was approved</td>
    </tr>
    <tr>
      <td>We <font color="blue">may also decide</font> to <font color="blue">enter into discount</font> or     formulary fee arrangements with payors, <font color="blue">which could</font> result in us receiving     lower or <font color="blue">discounted prices</font> for Prochieve^® and Striant^® or future products</td>
    </tr>
    <tr>
      <td>We <font color="blue"><font color="blue">face <font color="blue">significant</font></font> <font color="blue">competition</font> from <font color="blue">pharmaceutical</font></font> and <font color="blue">consumer product</font>     companies, which may <font color="blue">adversely</font> impact our market share</td>
    </tr>
    <tr>
      <td>We and our marketing partners compete against established <font color="blue">pharmaceutical</font> and     <font color="blue">consumer product</font> companies that market products <font color="blue">addressing</font> similar needs</td>
    </tr>
    <tr>
      <td>Further,  numerous  companies are developing, or may develop, enhanced     <font color="blue">delivery systems</font> and products that <font color="blue">compete with</font> our present and proposed     products</td>
    </tr>
    <tr>
      <td>It is possible that we may not have the resources to withstand     these and other <font color="blue">competitive forces</font></td>
    </tr>
    <tr>
      <td>Some of these <font color="blue">competitors</font> may possess     greater financial, research and technical resources than our company or our     partners</td>
    </tr>
    <tr>
      <td>Moreover,  these  companies  may  possess <font color="blue">greater marketing</font>     <font color="blue">cap<font color="blue">abilities</font> than</font> our company or our partners, including the resources to     implement extensive <font color="blue">advertising campaigns</font></td>
    </tr>
    <tr>
      <td>The  <font color="blue">pharmaceutical</font>  industry  is  subject  to  change <font color="blue">as new delivery</font>     <font color="blue">technologies</font> are developed, <font color="blue">new products enter</font> the market, generic versions     of <font color="blue">available drugs become available</font>, and <font color="blue">treatment paradigms evolve</font> to     reflect these and other <font color="blue">medical research discoveries</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">face <font color="blue">significant</font></font>     <font color="blue">competition</font> in all areas of our business</td>
    </tr>
    <tr>
      <td>The rapid pace of change in the     <font color="blue">pharmaceutical</font> industry <font color="blue">continually</font> creates <font color="blue">new <font color="blue">opportunities</font></font> for existing     <font color="blue">competitors</font> and start-ups, and can quickly render <font color="blue">existing products less</font>     valuable</td>
    </tr>
    <tr>
      <td>Customer <font color="blue">requirements</font> and physician and <font color="blue">patient preferences</font>     <font color="blue">continually</font> change <font color="blue">as new treatment options emerge</font>, are more or <font color="blue">less heavily</font>     promoted, and <font color="blue">become less expensive</font></td>
    </tr>
    <tr>
      <td>18       _________________________________________________________________       Crinone^®/Prochieve^®, a natural <font color="blue">progesterone</font> product, competes in markets     with other progestins, both synthetic and natural, that may be delivered     orally, by injection or by pharmacy compounded vaginal <font color="blue">suppository</font></td>
    </tr>
    <tr>
      <td>Some of     the   more   successful   orally-dosed   products   include   Provera®     (medroxy<font color="blue">progesterone</font> acetate) <font color="blue">marketed by</font> Pfizer Inc, Prometrium® (oral     micronized <font color="blue">progesterone</font>) <font color="blue">marketed by</font> Solvay SA, Prempro® (conjugated     estrogens/medroxy<font color="blue">progesterone</font> acetate tablets), and Premphase® (conjugated     estrogens/medroxy<font color="blue">progesterone</font> acetate tablets) <font color="blue">marketed by</font> Wyeth</td>
    </tr>
    <tr>
      <td>Striant^® <font color="blue">competes against</font> other <font color="blue"><font color="blue">testosterone</font> products</font> that can be delivered     by  injection, transdermal patch and <font color="blue">transdermal gel</font></td>
    </tr>
    <tr>
      <td>Some of the more     successful  <font color="blue"><font color="blue">testosterone</font> products</font> include AndroGel® (<font color="blue">testosterone</font> gel)     marketed  by  Unimed Pharmaceuticals, Inc, Testim® (<font color="blue">testosterone</font> gel)     <font color="blue">marketed by</font> Auxilium Pharmaceuticals Inc, and Androderm® (<font color="blue">testosterone</font>     transdermal system) <font color="blue">marketed by</font> Watson Pharma, Inc</td>
    </tr>
    <tr>
      <td><font color="blue">Competition </font>is based     <font color="blue">primarily on delivery method</font></td>
    </tr>
    <tr>
      <td><font color="blue">Transdermal </font><font color="blue">testosterone</font> gels currently have     the <font color="blue">largest market</font> share and transdermal <font color="blue">testosterone</font> patches have the next     <font color="blue">largest market</font> share, <font color="blue">followed by injectable products</font></td>
    </tr>
    <tr>
      <td>Striant^® is priced     <font color="blue">comparably</font> to the gels and patches</td>
    </tr>
    <tr>
      <td>In the past, certain studies of female hormone <font color="blue">replacement</font> therapy products,     such as estrogen, have reported an increase in health risks</td>
    </tr>
    <tr>
      <td><font color="blue">Progesterone </font>is     a natural female hormone, present at normal levels in <font color="blue">most women through</font>     their lifetimes</td>
    </tr>
    <tr>
      <td>However, some women require <font color="blue">progesterone</font> <font color="blue">supplementation</font>     due to a natural or chemical-related <font color="blue">progesterone</font> deficiency</td>
    </tr>
    <tr>
      <td>It is possible     that data suggesting risks or <font color="blue">problems may come</font> to light in the <font color="blue">future which</font>     <font color="blue">could <font color="blue">demonstrate</font></font> a <font color="blue">health risk associated with</font> <font color="blue">progesterone</font> or progestin     <font color="blue">supplementation</font> or our 8prca and 4prca <font color="blue">progesterone</font> gels</td>
    </tr>
    <tr>
      <td>It is <font color="blue">also possible</font> that     <font color="blue">future study</font> results for hormone <font color="blue">replacement</font> therapy could be negative and     could result in <font color="blue"><font color="blue">negative publicity</font> about</font> the risks and benefits of hormone     <font color="blue">replacement</font> therapy</td>
    </tr>
    <tr>
      <td>As a result, physicians and patients may not wish to     prescribe or use progestins, including our <font color="blue">progesterone</font> gels</td>
    </tr>
    <tr>
      <td>Similarly, while <font color="blue">testosterone</font> is a natural male hormone, present at normal     levels in <font color="blue">most men through</font> their lifetime, some men require <font color="blue">testosterone</font>     <font color="blue">replacement</font> therapy, or TRT, to normalize their <font color="blue">testosterone</font> levels</td>
    </tr>
    <tr>
      <td>It is     possible that data suggesting risks or <font color="blue">problems may come</font> to light in the     future  which  could  <font color="blue">demonstrate</font> a <font color="blue">health risk associated with</font> TRT or     Striant^®</td>
    </tr>
    <tr>
      <td>It  is <font color="blue">also possible</font> that <font color="blue">future study</font> results for hormone     <font color="blue">replacement</font> therapy could be negative and could result in <font color="blue">negative publicity</font>     about the risks and benefits of hormone <font color="blue">replacement</font> therapy</td>
    </tr>
    <tr>
      <td>In <font color="blue">addition investors may become concerned about</font> these issues and decide to     sell our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>These <font color="blue">factors could <font color="blue">adversely</font> affect</font> our business and     the price of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We may be exposed to <font color="blue">product liability</font> claims</td>
    </tr>
    <tr>
      <td>We  could  be exposed to future <font color="blue">product liability</font> claims <font color="blue">by consumers</font></td>
    </tr>
    <tr>
      <td>Although we presently maintain <font color="blue">product liability</font> <font color="blue">insurance coverage</font> in the     amount of dlra15 million, such insurance may not be sufficient to cover all     <font color="blue">possible li<font color="blue">abilities</font></font></td>
    </tr>
    <tr>
      <td>An <font color="blue">award against us</font> in an <font color="blue">amount greater than</font> our     <font color="blue"><font color="blue">insurance coverage</font> could</font> have a material adverse effect on our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>Some customers require us to have a <font color="blue">minimum level</font> of <font color="blue">product liability</font>     <font color="blue">insurance coverage</font> before they <font color="blue">will purchase</font> or accept our products for     <font color="blue">distribution</font></td>
    </tr>
    <tr>
      <td>If we fail to satisfy insurance <font color="blue">requirements</font>, our ability to     achieve broad <font color="blue">distribution</font> of our <font color="blue">products could</font> be limited</td>
    </tr>
    <tr>
      <td>This could have     a material adverse effect upon our business and <font color="blue">financial condition</font></td>
    </tr>
    <tr>
      <td>19       _________________________________________________________________       Steps <font color="blue">taken by us</font> to protect our <font color="blue"><font color="blue"><font color="blue">proprietary</font> rights</font> might</font> not be adequate,     in which case <font color="blue">competitors</font> may <font color="blue">infringe on</font> our rights or develop similar     products</td>
    </tr>
    <tr>
      <td><font color="blue">The United States </font>and foreign patents upon which our original     <font color="blue">Bioadhesive Delivery System </font>was based have expired</td>
    </tr>
    <tr>
      <td>Our success and <font color="blue">competitive position</font> are partially <font color="blue">dependent</font> on our ability     to protect our <font color="blue"><font color="blue">proprietary</font> position</font> for our <font color="blue">technology</font>, products and product     <font color="blue">candidates</font></td>
    </tr>
    <tr>
      <td>We <font color="blue">rely primarily on</font> a <font color="blue">combination</font> of patents, <font color="blue">trademarks</font>,     copyrights, trade secret laws, third-party confidentiality and <font color="blue">nondisclosure</font>     <font color="blue">agreement</font>s, and other methods to protect our <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>The steps     we take to protect our <font color="blue"><font color="blue">proprietary</font> rights</font>, however, may not be adequate</td>
    </tr>
    <tr>
      <td>Third  <font color="blue">parties may infringe</font> or <font color="blue">mis<font color="blue">appropriate</font></font> our patents, copyrights,     <font color="blue">trademarks</font>, and similar <font color="blue"><font color="blue">proprietary</font> rights</font></td>
    </tr>
    <tr>
      <td>Moreover, we may not be able or     willing, for financial, legal or other reasons, to enforce our rights</td>
    </tr>
    <tr>
      <td>To     date, we have never been a party to a <font color="blue"><font color="blue">proprietary</font> rights</font> action</td>
    </tr>
    <tr>
      <td>Bio-Mimetics, Inc</td>
    </tr>
    <tr>
      <td>held the patent upon which our original Bioadhesive     Delivery System, or BDS, was based and <font color="blue">granted us</font> a <font color="blue">license under</font> that     patent</td>
    </tr>
    <tr>
      <td>Bio-Mimetics’ <font color="blue">patent contained broad</font> claims <font color="blue">covering controlled</font>     <font color="blue">release products</font> that include a <font color="blue">bioadhesive</font></td>
    </tr>
    <tr>
      <td>However, this <font color="blue">United States     </font>patent and its <font color="blue">corresponding foreign patents expired</font> in November 2003</td>
    </tr>
    <tr>
      <td><font color="blue">Based     </font>upon the expiration of the original Bio-Mimetics patent, other <font color="blue">parties will</font>     be permitted to make, use or <font color="blue"><font color="blue">sell products</font> covered by</font> the claims of the     Bio-Mimetics patent, subject to other patents, including those which we     hold</td>
    </tr>
    <tr>
      <td>We have obtained <font color="blue">numerous patents with</font> claims <font color="blue">covering improved</font>     methods of <font color="blue">formulating</font> and delivering <font color="blue">therapeutic</font> compounds using the BDS     We <font color="blue">cannot assure</font> you that any of these <font color="blue">patents will enable us</font> to prevent     <font color="blue">infringement</font>, or that our <font color="blue">competitors</font> will not develop <font color="blue">alternative methods</font>     of delivering compounds, potentially resulting in <font color="blue">competitive products</font>     outside the protection that may be <font color="blue">afforded by</font> our patents</td>
    </tr>
    <tr>
      <td>Other companies     may in<font color="blue">dependent</font>ly develop or obtain patent or similar rights to equivalent     or superior <font color="blue">technologies</font> or processes</td>
    </tr>
    <tr>
      <td>Additionally, although we believe     that our <font color="blue">patented <font color="blue">technology</font></font> has been in<font color="blue">dependent</font>ly developed and does not     <font color="blue">infringe on</font> the <font color="blue"><font color="blue">proprietary</font> rights</font> of others, we <font color="blue">cannot assure</font> you that our     products do not and will not <font color="blue">infringe on</font> the <font color="blue"><font color="blue">proprietary</font> rights</font> of others</td>
    </tr>
    <tr>
      <td>In the event of <font color="blue">infringement</font>, we may be required to modify our <font color="blue">technology</font> or     products, obtain licenses or pay license fees</td>
    </tr>
    <tr>
      <td>We may not be able to do so     in a <font color="blue">timely manner</font> or upon acceptable terms and <font color="blue">conditions</font></td>
    </tr>
    <tr>
      <td>This may have a     material adverse effect on our <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The standards that the <font color="blue">US Patent and Trademark Office </font>and its foreign     <font color="blue">counterparts</font> use to grant patents are not always applied <font color="blue">predictably</font> or     uniformly and can change</td>
    </tr>
    <tr>
      <td><font color="blue">Limitations </font><font color="blue">on patent protection</font> in some countries     outside the US, and the <font color="blue">differences</font> in what <font color="blue">constitutes patentable</font> subject     matter in these countries, may limit the protection we seek outside of the     US For example, methods of <font color="blue">treating humans</font> are not patentable subject     matter in many <font color="blue">countries outside</font> of the US In addition, laws of foreign     <font color="blue">countries may</font> not protect our <font color="blue">intellectual property</font> to the <font color="blue">same extent as</font>     would laws of the US In determining whether or not to seek a patent or to     license any patent in a <font color="blue">particular foreign country</font>, we weigh the relevant     costs and benefits, and consider, among other things, the <font color="blue">market potential</font>     of  our  product  <font color="blue">candidates</font>  in  the  <font color="blue">jurisdiction</font>  and the scope and     <font color="blue">enforceability</font> of patent protection <font color="blue">afforded by</font> the law of the <font color="blue">jurisdiction</font></td>
    </tr>
    <tr>
      <td>We  own  or are <font color="blue">seeking registration</font> of the following as <font color="blue">trademarks</font> in     <font color="blue">countries throughout</font> the world: Crinone^®, Prochieve^®, Striant^®, and     Striant^®  SR  These  <font color="blue">trademarks</font>, however, may not <font color="blue">afford us adequate</font>     protection or we may not have the <font color="blue">financial resources</font> to enforce our rights     under these <font color="blue">trademarks</font></td>
    </tr>
    <tr>
      <td>20       _________________________________________________________________       We are subject to government regulation, <font color="blue">which could</font> affect our ability to     <font color="blue">sell products</font></td>
    </tr>
    <tr>
      <td>Nearly <font color="blue">every aspect</font> of the <font color="blue">development</font>, <font color="blue">manufacture</font> and <font color="blue">commercialization</font> of     our approved <font color="blue">pharmaceutical</font> products is subject to time-consuming and costly     <font color="blue">regulation by various governmental entities</font>, including the Food and Drug     Administration,  or FDA, the Drug Enforcement Administration and state     agencies, as well as <font color="blue">regulatory</font> agencies in those foreign countries in which     our products are <font color="blue"><font color="blue">manufacture</font>d</font> or <font color="blue">distributed</font></td>
    </tr>
    <tr>
      <td>The FDA has the power to seize     <font color="blue">adulterated</font> or <font color="blue">misbranded products</font> and <font color="blue">unapproved new drugs</font>, to require     their <font color="blue">recall from</font> the market, to <font color="blue">enjoin further <font color="blue">manufacture</font></font> or sale, and to     <font color="blue">publicize certain facts concerning</font> a product</td>
    </tr>
    <tr>
      <td>We <font color="blue">employ various quality control measures</font> in our efforts to ensure that our     <font color="blue">products conform</font> to their <font color="blue">intended <font color="blue">specifications</font></font> and meet the standards     <font color="blue">proscribed by applicable governmental <font color="blue">regulations</font></font>, including FDA’s current     <font color="blue">Good Manufacturing Practices </font><font color="blue">regulations</font></td>
    </tr>
    <tr>
      <td><font color="blue">Notwithstanding </font>our efforts, our     products or the <font color="blue">ingredients</font> we <font color="blue">purchase from</font> our suppliers for inclusion in     our  products  <font color="blue">may contain undetected defects</font> or non-conformities with     <font color="blue">specifications</font></td>
    </tr>
    <tr>
      <td>Such defects or non-conformities could compel us to recall     the  <font color="blue">affected product</font>, make changes to or restrict <font color="blue">distribution</font> of the     product, or take other <font color="blue">remedial actions</font></td>
    </tr>
    <tr>
      <td>The occurrence of <font color="blue">such events may</font>     harm our <font color="blue">relations with</font> or result in the loss of customers, injure our     reputation, impair market acceptance of our products, harm our financial     results, and, in certain <font color="blue">circumstances</font>, expose us to <font color="blue">product liability</font> or     other claims</td>
    </tr>
    <tr>
      <td>The <font color="blue">development</font> of our <font color="blue">pharmaceutical</font> products, including the <font color="blue">development</font> of     Prochieve^® 8prca for the prevention of <font color="blue">preterm birth</font>, is uncertain and subject     to a number of <font color="blue"><font color="blue">significant</font> risks</font></td>
    </tr>
    <tr>
      <td>Some of our <font color="blue">pharmaceutical</font> products are in various stages of <font color="blue">development</font></td>
    </tr>
    <tr>
      <td>In     the United States and most foreign countries, we must complete extensive     human <font color="blue">clinical trials</font> that <font color="blue">demonstrate</font> the safety and efficacy of a product     in order to apply for <font color="blue">regulatory</font> approval to market the product</td>
    </tr>
    <tr>
      <td>The process of developing product <font color="blue">candidates</font> involves a degree of risk and     may take <font color="blue">several years</font></td>
    </tr>
    <tr>
      <td>Product <font color="blue">candidates</font> that appear promising in the     early  phases  of <font color="blue">development</font> may fail to reach the market for several     reasons, including:           ·       Clinical <font color="blue">trials may show</font> our product <font color="blue">candidates</font> to be <font color="blue">in<font color="blue">effective</font></font> or to have     harmful side effects;       ·       Product <font color="blue">candidates</font> may fail to receive <font color="blue">regulatory</font> approvals required to     bring the products to market;       ·       <font color="blue">Manufacturing  </font>costs  or other <font color="blue">factors may</font> make our product <font color="blue">candidates</font>     uneconomical; and       ·       The  <font color="blue">proprietary</font>  rights  of  others  and their <font color="blue">competing products</font> and     <font color="blue">technologies</font> may prevent our product <font color="blue">candidates</font> from being <font color="blue"><font color="blue">effective</font>ly</font>     <font color="blue">commercialize</font>d</td>
    </tr>
    <tr>
      <td>Clinical results are <font color="blue">frequently susceptible</font> to     varying  <font color="blue">interpretations</font>  that  may delay, limit or prevent <font color="blue">regulatory</font>     approvals</td>
    </tr>
    <tr>
      <td>The length of time <font color="blue">necessary</font> to complete <font color="blue">clinical trials</font> and to submit an     <font color="blue">application</font> for <font color="blue">marketing approval</font> for a <font color="blue">final decision by</font> a <font color="blue">regulatory</font>     <font color="blue">authority varies <font color="blue">significant</font>ly</font> and may be <font color="blue">difficult</font> to predict</td>
    </tr>
    <tr>
      <td>The speed     with which we can complete <font color="blue">clinical trials</font> and <font color="blue">application</font>s for marketing     approval will depend on several factors, including the following:           ·       The  rate  of patient <font color="blue">enrollment</font>, which is a function of many factors,     including the size of the <font color="blue">patient population</font>, the proximity of patients to     <font color="blue">clinical sites</font>, the <font color="blue">eligibility criteria</font> for the study, and the nature of     the <font color="blue">study protocol</font>;       ·       <font color="blue">Institutional </font><font color="blue">review board</font>, or IRB, approval of the <font color="blue">study protocol</font> and the     <font color="blue">informed consent</font> form;       ·       Prior <font color="blue">regulatory</font> agency review and approval;       ·       <font color="blue">Analysis </font>of data obtained from clinical <font color="blue">activities</font>, which are susceptible to     varying <font color="blue">interpretations</font> and which <font color="blue">interpretations</font> could delay, limit or     prevent <font color="blue">regulatory</font> approval;       ·       Changes in the policies of <font color="blue">regulatory</font> <font color="blue">authorities</font> for <font color="blue">drug approval during</font>     the period of <font color="blue">product <font color="blue">development</font></font>; and       21       _________________________________________________________________       ·       The <font color="blue">availability</font> of skilled and experienced staff to conduct and monitor     <font color="blue">clinical studies</font> and to prepare the <font color="blue">appropriate</font> <font color="blue">regulatory</font> <font color="blue">application</font>s</td>
    </tr>
    <tr>
      <td>In  addition, developing product <font color="blue">candidates</font> is very expensive and will     continue to have a <font color="blue"><font color="blue">significant</font> <font color="blue">impact on</font></font> our ability to <font color="blue">generate profits</font></td>
    </tr>
    <tr>
      <td>Factors <font color="blue">affecting</font> our <font color="blue">product <font color="blue">development</font></font> expenses include:           ·       Our ability to raise any <font color="blue"><font color="blue">additional</font> funds</font> that we need to complete our     trials;       ·       The  number  and outcome of <font color="blue">clinical trials</font> conducted by us and/or our     <font color="blue">collaborators</font>;       ·       The number of products we may have in clinical <font color="blue">development</font>;       ·       In-licensing or other partnership <font color="blue">activities</font>, including the timing and     amount of related <font color="blue">development</font> funding, license fees or <font color="blue">milestone payments</font>;     and       ·       Future levels of our revenue</td>
    </tr>
    <tr>
      <td>Clinical trials are expensive and can take years to complete, and there is     no guarantee that the <font color="blue">clinical trials</font> will <font color="blue">demonstrate</font> sufficient safety     and/or  efficacy of the products to meet FDA <font color="blue">requirements</font>, or those of     foreign <font color="blue">regulatory</font> <font color="blue">authorities</font></td>
    </tr>
    <tr>
      <td>In  November  2003,  the  <font color="blue">Company  </font>announced a <font color="blue">Phase III </font>multi-center,     randomized, double-blind, placebo-controlled, clinical trial designed to     assess the efficacy, safety and <font color="blue">tolerability</font> of Prochieve^® 8prca (<font color="blue">progesterone</font>     gel) in <font color="blue">preventing preterm delivery</font> in <font color="blue">pregnant women</font> who are at increased     risk for <font color="blue">preterm birth</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">study protocol</font> defines “at risk” patients as     <font color="blue">pregnant women</font> who have either a history of a <font color="blue">spontaneous preterm delivery</font>,     or who have a <font color="blue">cervical length</font> of 2dtta5 cm or less, as measured by transvaginal     ultrasound, with the <font color="blue">current pregnancy</font></td>
    </tr>
    <tr>
      <td>Patients are randomized to receive     either Prochieve^® 8prca or placebo</td>
    </tr>
    <tr>
      <td><font color="blue">Treatment </font>is initiated between 18 and 22     weeks of gestation and administered daily until delivery, withdrawal from     the study, <font color="blue">development</font> of <font color="blue">preterm rupture</font> of the membranes, or until 37     completed weeks of gestation</td>
    </tr>
    <tr>
      <td>This study is designed to enroll 636 patients;     414 patients were <font color="blue">enrolled at</font> the end of February, 2006</td>
    </tr>
    <tr>
      <td><font color="blue">From October </font>2005     through <font color="blue">February </font>2006, <font color="blue">enrollment</font> averaged 35 patients per month, a rate the     Company expects to maintain <font color="blue">going forward through</font> the addition of new study     centers and execution of its study-related marketing efforts</td>
    </tr>
    <tr>
      <td><font color="blue">From October </font>    2005 through <font color="blue">February </font>2006, the Company added 10 study centers</td>
    </tr>
    <tr>
      <td>The <font color="blue">Company  </font>   had  53  study centers (42 domestic and 11 foreign) open at the end of     February, 2006, and plans to open up to 10 more in <font color="blue">March and April </font>2006</td>
    </tr>
    <tr>
      <td>The     Company projects that <font color="blue">enrollment</font> in the <font color="blue">preterm study will</font> be complete by     the end of third quarter 2006</td>
    </tr>
    <tr>
      <td><font color="blue">The Company </font>expects, if positive results are     obtained, to file with the FDA for a <font color="blue">label <font color="blue">indication</font></font> in mid-2007</td>
    </tr>
    <tr>
      <td><font color="blue">Because     </font>there is <font color="blue">no approved treatment</font> for <font color="blue">preterm birth</font>, and because of the growing     incidence, and economic and <font color="blue">social impact</font>, of this problem, the Company is     hopeful that the FDA will grant an expedited review during 2007</td>
    </tr>
    <tr>
      <td><font color="blue">Enrollment     </font>of patients may not be completed in a <font color="blue">timely manner</font> and the study may not be     successful</td>
    </tr>
    <tr>
      <td>If  the  study  does  not <font color="blue">demonstrate</font> that Prochieve^® 8prca     (<font color="blue">progesterone</font> gel) prevents preterm delivery in <font color="blue">pregnant women</font> who are at     increased  risk  for <font color="blue">preterm birth</font>, our <font color="blue">future sales <font color="blue">opportunities</font></font> and     <font color="blue"><font color="blue">profitability</font> would</font> be <font color="blue">reduced <font color="blue">significant</font>ly</font></td>
    </tr>
    <tr>
      <td>We may experience <font color="blue">adverse events</font> in <font color="blue">clinical trials</font>, <font color="blue">which could</font> delay or     halt our <font color="blue">product <font color="blue">development</font></font></td>
    </tr>
    <tr>
      <td>Our product <font color="blue">candidates</font> may produce serious <font color="blue">adverse events</font></td>
    </tr>
    <tr>
      <td>These adverse     events  could  interrupt, delay or halt <font color="blue">clinical trials</font> of our product     <font color="blue">candidates</font> and could result in FDA or other <font color="blue">regulatory</font> <font color="blue">authorities</font> denying     approval of our product <font color="blue">candidates</font> for any or all <font color="blue">targeted <font color="blue"><font color="blue">indication</font>s</font></font></td>
    </tr>
    <tr>
      <td>An     IRB or in<font color="blue">dependent</font> data safety monitoring board, the FDA, other <font color="blue">regulatory</font>     <font color="blue">authorities</font>, or we ourselves may suspend or terminate <font color="blue">clinical trials</font> at any     time</td>
    </tr>
    <tr>
      <td>Our product <font color="blue">candidates</font> may prove not to be safe for human use</td>
    </tr>
    <tr>
      <td>Delays or failures in obtaining <font color="blue">regulatory</font> approvals may delay or prevent     marketing of the products that we are developing</td>
    </tr>
    <tr>
      <td>Other  than Prochieve^®, all of our product <font color="blue">candidates</font> are in clinical     <font color="blue">development</font> and have not received <font color="blue">regulatory</font> approval from the FDA or any     foreign <font color="blue">regulatory</font> authority</td>
    </tr>
    <tr>
      <td>The <font color="blue">regulatory</font> approval process typically is     <font color="blue">extremely expensive</font>, takes many years, and the timing or likelihood of any     <font color="blue">approval cannot</font> be <font color="blue">accurately predicted</font></td>
    </tr>
    <tr>
      <td>Delays in obtaining <font color="blue">regulatory</font>     approval can be extremely costly in terms of lost sales <font color="blue">opportunities</font> and     increased clinical trial costs</td>
    </tr>
    <tr>
      <td>If we fail to obtain <font color="blue">regulatory</font> approval for     our  current  or future product <font color="blue">candidates</font> or <font color="blue">expanded <font color="blue"><font color="blue">indication</font>s</font></font> for     <font color="blue">currently marketed products</font>, we will be unable to market and sell such     products and <font color="blue"><font color="blue">indication</font>s</font> and <font color="blue">therefore may never</font> be profitable</td>
    </tr>
    <tr>
      <td>22       _________________________________________________________________       As part of the <font color="blue">regulatory</font> approval process, we must conduct <font color="blue">clinical trials</font>     for <font color="blue">each product candidate</font> to <font color="blue">demonstrate</font> safety and efficacy</td>
    </tr>
    <tr>
      <td>The number of     clinical  trials that will be required <font color="blue">varies depending on</font> the product     candidate,  the <font color="blue">indication</font> being evaluated, the trial results, and the     <font color="blue">regulations</font> applicable to any <font color="blue">particular product candidate</font></td>
    </tr>
    <tr>
      <td>The results of initial <font color="blue">clinical trials</font> of our product <font color="blue">candidates</font> do not     <font color="blue"><font color="blue">necessarily</font> predict</font> the results of later-stage <font color="blue">clinical trials</font></td>
    </tr>
    <tr>
      <td><font color="blue">Product     </font><font color="blue">candidates</font> in <font color="blue">later stages</font> of <font color="blue">clinical trials</font> may fail to show the desired     safety and <font color="blue">efficacy despite</font> having progressed <font color="blue">through initial clinical</font>     trials</td>
    </tr>
    <tr>
      <td>The  data  collected  from the <font color="blue">clinical trials</font> of our product     <font color="blue">candidates</font>  may  not  be sufficient to support FDA or other <font color="blue">regulatory</font>     approval</td>
    </tr>
    <tr>
      <td>In addition, the <font color="blue">continuation</font> of a <font color="blue">particular study</font> after review     by an IRB or in<font color="blue">dependent</font> data safety monitoring board does not <font color="blue">necessarily</font>     indicate that our product candidate will achieve the clinical endpoint</td>
    </tr>
    <tr>
      <td>The FDA and other <font color="blue">regulatory</font> agencies can delay, limit or <font color="blue">deny approval</font> for     many reasons, including:           ·       A <font color="blue">product candidate may</font> not be deemed to be safe or <font color="blue">effective</font>;       ·       The <font color="blue">manufacturing processes</font> or <font color="blue">facilities</font> we have <font color="blue">selected may</font> not meet the     applicable <font color="blue">requirements</font>; and       ·       <font color="blue">Changes  </font>in their approval policies or adoption of new <font color="blue">regulations</font> may     require <font color="blue">additional</font> <font color="blue">clinical trials</font> or other data</td>
    </tr>
    <tr>
      <td>Any  delay  in, or failure to receive, approval for any of our product     <font color="blue">candidates</font>  could  prevent  us  <font color="blue">from growing</font> our revenues or achieving     <font color="blue">profitability</font></td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent</font> on a <font color="blue">principal supplier</font>, the loss of <font color="blue"><font color="blue">which could</font> impair</font> our     ability to <font color="blue">manufacture</font> and sell our products</td>
    </tr>
    <tr>
      <td>Medical grade, cross-linked <font color="blue">polycarbophil</font>, the <font color="blue">polymer used</font> in our BDS-based     products is currently <font color="blue">available from</font> only one supplier, Noveon, Inc, or     Noveon</td>
    </tr>
    <tr>
      <td>We believe that Noveon <font color="blue">will supply as</font> much of the material as we     require because our <font color="blue">products rank among</font> the highest value-added uses of the     polymer</td>
    </tr>
    <tr>
      <td>In the event that Noveon cannot or will not <font color="blue">supply enough</font> of the     product  to satisfy our needs, we will be required to <font color="blue">seek alternative</font>     sources of <font color="blue">polycarbophil</font></td>
    </tr>
    <tr>
      <td>An <font color="blue">alternative source</font> of <font color="blue">polycarbophil</font> may not be     <font color="blue">available on</font> satisfactory terms or at all, <font color="blue">which would impair</font> our ability to     <font color="blue">manufacture</font> and sell our products</td>
    </tr>
    <tr>
      <td>We are <font color="blue">dependent</font> upon third-party developers and <font color="blue">manufacture</font>rs, the loss of     <font color="blue">which could</font> result in a loss of revenues</td>
    </tr>
    <tr>
      <td>We <font color="blue">rely on third parties</font> to develop and <font color="blue">manufacture</font> our products</td>
    </tr>
    <tr>
      <td><font color="blue">These     </font><font color="blue">third parties may</font> not be able to satisfy our needs in the future, and we may     not be able to find or obtain FDA approval of <font color="blue">alternate developers</font> and     <font color="blue">manufacture</font>rs</td>
    </tr>
    <tr>
      <td>Delays in the <font color="blue">development</font> and <font color="blue">manufacture</font> of our products     could have a material adverse effect on our business</td>
    </tr>
    <tr>
      <td>This <font color="blue">reliance on third</font>     <font color="blue">parties could</font> have an adverse effect on our <font color="blue">profit margins</font></td>
    </tr>
    <tr>
      <td>Any interruption     in the <font color="blue">manufacture</font> of our products would impair our ability to deliver our     products to <font color="blue">customers on</font> a timely and <font color="blue">competitive basis</font>, and could result in     the loss of revenues</td>
    </tr>
    <tr>
      <td>The  loss of our <font color="blue">key executives could</font> have a <font color="blue"><font color="blue">significant</font> <font color="blue">impact on</font></font> our     company</td>
    </tr>
    <tr>
      <td>Our <font color="blue">success depends</font> in large part upon the <font color="blue">abilities</font> and <font color="blue">continued service</font>     of our <font color="blue">executive officers</font> and other key employees, particularly Robert S     Mills, our <font color="blue">President and Chief Executive Officer</font></td>
    </tr>
    <tr>
      <td>We have <font color="blue">entered into</font> an     employment <font color="blue">agreement</font> with Mr</td>
    </tr>
    <tr>
      <td>Mills, <font color="blue">which expires</font> in March 2007</td>
    </tr>
    <tr>
      <td>The loss     of services of our officers and <font color="blue">directors could</font> have a material adverse     effect on our business and prospects</td>
    </tr>
    <tr>
      <td>23       _________________________________________________________________       We may be limited in our use of our net operating <font color="blue">loss carryforwards</font></td>
    </tr>
    <tr>
      <td>As of <font color="blue">December </font>31, 2005, we had <font color="blue">certain net</font> operating <font color="blue">loss carryforwards</font> of     <font color="blue">approximately</font>  dlra128 million that may be used to reduce our future US     federal income tax li<font color="blue">abilities</font></td>
    </tr>
    <tr>
      <td>Our ability to use these <font color="blue">loss carryforwards</font>     to reduce our future US federal income tax li<font color="blue">abilities</font> could be lost if we     were to experience more than a 50prca change in <font color="blue">ownership within</font> the meaning of     Section 382(g) of the <font color="blue">Internal Revenue Code</font></td>
    </tr>
    <tr>
      <td>If we were to lose the benefits     of these <font color="blue">loss carryforwards</font>, our <font color="blue">future earnings</font> and <font color="blue">cash resources would</font> be     <font color="blue">materially</font> and <font color="blue"><font color="blue">adversely</font> affected</font></td>
    </tr>
    <tr>
      <td>Sales of large amounts of <font color="blue">common stock</font> may <font color="blue">adversely</font> affect our market     price</td>
    </tr>
    <tr>
      <td>The issuance of <font color="blue">preferred stock</font> may <font color="blue">adversely</font> affect rights of common     <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>On March 10, 2006, we <font color="blue">entered into</font> a <font color="blue"><font color="blue">Securities Purchase Agreement</font> </font>with     <font color="blue">certain investors</font> for the <font color="blue">private placement</font> of 7cmam428cmam220 shares of our     <font color="blue">common stock</font>, par value $</td>
    </tr>
    <tr>
      <td>01 per share (the “Shares”), at a price of dlra4dtta04     per share and warrants to purchase 1cmam857cmam041 shares of <font color="blue">common stock</font> (the     “Warrants”)</td>
    </tr>
    <tr>
      <td>We expect gross <font color="blue">proceeds from</font> the sale of <font color="blue">the Shares </font>will be     <font color="blue">approximately</font> dlra30 million</td>
    </tr>
    <tr>
      <td><font color="blue">The Warrants </font>are exercisable for our <font color="blue">common stock</font>     at dlra5dtta39 per share beginning 180 days from the date they are issued, which     is  expected to occur on or about March 15, 2006, and expiring 5 years     thereafter</td>
    </tr>
    <tr>
      <td>The <font color="blue">exercise price</font> and number of shares <font color="blue">issuable upon</font> exercise     are subject to <font color="blue">adjustment</font> in the event of stock split, stock dividend,     recapitalization, reclassification, <font color="blue">combination</font> or exchange of shares,     reorganization, liquidation, dissolution, consolidation, or merger</td>
    </tr>
    <tr>
      <td><font color="blue">Under     </font>the terms of the <font color="blue">Securities Purchase Agreement</font>, we have agreed to file,     within 30 days, a <font color="blue">registration statement with</font> the Securities and Exchange     Commission to register for resale <font color="blue">the Shares </font>and the shares of <font color="blue">common stock</font>     <font color="blue">issuable upon</font> the exercise of the Warrants, <font color="blue">which registration statement</font> is     required under the <font color="blue"><font color="blue">Securities Purchase Agreement</font> </font>to become <font color="blue">effective</font> within     120 days following the closing</td>
    </tr>
    <tr>
      <td>We will be required to <font color="blue">pay certain cash</font>     penalties  if  we  do  not meet our <font color="blue">registration obligations under</font> the     <font color="blue">Securities Purchase Agreement</font></td>
    </tr>
    <tr>
      <td><font color="blue">As of March </font>3, 2006, we had 41cmam754cmam784 shares of <font color="blue">common stock</font> outstanding,     of which 41cmam354cmam784 shares were <font color="blue">freely tradable</font></td>
    </tr>
    <tr>
      <td><font color="blue">Approximately </font>400cmam000     shares  of our <font color="blue">common stock</font> are restricted securities, but may be sold     pursuant  to Rule 144 under <font color="blue">the <font color="blue">Securities Act</font></font> of 1933, as amended, or     another exemption under <font color="blue">the <font color="blue">Securities Act</font></font></td>
    </tr>
    <tr>
      <td>We also have the following     securities outstanding: series B <font color="blue">convertible <font color="blue">preferred stock</font></font>, series C     <font color="blue">convertible <font color="blue">preferred stock</font></font>, series E <font color="blue">convertible <font color="blue">preferred stock</font></font>, warrants     and options</td>
    </tr>
    <tr>
      <td>If all of these securities are exercised or converted, an     <font color="blue">additional</font> 10cmam845cmam895 shares of <font color="blue">common stock</font> will be outstanding, all of     <font color="blue">which will</font> have <font color="blue">been registered</font> for <font color="blue">resale under</font> <font color="blue">the <font color="blue">Securities Act</font></font></td>
    </tr>
    <tr>
      <td><font color="blue">When     </font>issued, these <font color="blue">registered <font color="blue">shares will</font></font> be <font color="blue">freely tradable</font> and restricted     <font color="blue">shares will</font> be <font color="blue">saleable under</font> Rule 144 in the future</td>
    </tr>
    <tr>
      <td>The exercise and     <font color="blue">conversion</font> of these securities is likely to dilute the <font color="blue">book value per</font> share     of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>In addition, the existence of these <font color="blue">securities may</font>     <font color="blue">adversely</font>  affect  the  <font color="blue">terms on which</font> we can obtain <font color="blue">additional</font> equity     financing</td>
    </tr>
    <tr>
      <td>In March 2002, our <font color="blue">Board of Directors </font><font color="blue">authorized shares</font> of series D junior     <font color="blue">participating</font>  preferred  stock  in  <font color="blue">connection with</font> its adoption of a     <font color="blue">stockholder rights</font> plan, under which we <font color="blue">issued rights</font> to <font color="blue">purchase series</font> D     <font color="blue">convertible <font color="blue">preferred stock</font></font> to holders of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Upon certain     triggering events, such rights become exercisable to <font color="blue">purchase shares</font> of     <font color="blue">common stock</font> (or, in the <font color="blue">discretion</font> of our Board of Directors, series D     <font color="blue">convertible <font color="blue">preferred stock</font></font>) at a <font color="blue">price substantially discounted from</font> the     <font color="blue">then current market price</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Under our <font color="blue">certificate</font> of <font color="blue">in<font color="blue">corporation</font></font>, our <font color="blue">Board of Directors </font>has the     authority  to issue up to 1dtta0 million shares of <font color="blue">preferred stock</font> and to     determine the price, rights, preferences and privileges of those shares     without any <font color="blue">further vote</font> or <font color="blue">action by</font> our <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>The rights of the     holders of <font color="blue">common stock</font> are subject to, and may be <font color="blue"><font color="blue">adversely</font> affected</font> by,     the rights of the holders of any shares of <font color="blue">preferred stock</font> that may be     issued in the future</td>
    </tr>
    <tr>
      <td>While we have <font color="blue">no present intention</font> to authorize any     <font color="blue">additional</font> series of <font color="blue">preferred stock</font>, such <font color="blue">preferred stock</font>, if authorized,     may have other rights, including <font color="blue">economic rights senior</font> to the <font color="blue">common stock</font>,     and, as a result, their <font color="blue">issuance could</font> have a material adverse effect on the     <font color="blue">market value</font> of our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>24       _________________________________________________________________           Changes in, or <font color="blue">interpretations</font> of, <font color="blue"><font color="blue">accounting</font> principles could</font> result in     <font color="blue">unfavorable <font color="blue">accounting</font> charges</font></td>
    </tr>
    <tr>
      <td>We prepare our <font color="blue">consolidated financial statements</font> in <font color="blue">conformity with</font> US     <font color="blue">generally accepted <font color="blue">accounting</font> principles</font></td>
    </tr>
    <tr>
      <td>These principles are subject to     interpretation by the SEC and various bodies formed to interpret and create     <font color="blue">appropriate</font> <font color="blue">accounting</font> principles</td>
    </tr>
    <tr>
      <td>A change in these principles can have a     <font color="blue">significant</font> effect on our reported results and <font color="blue">may even retroactively affect</font>     <font color="blue">previously</font> reported <font color="blue">transactions</font></td>
    </tr>
    <tr>
      <td>Our <font color="blue">accounting</font> principles that recently     have been or may be <font color="blue">affected by</font> changes in the <font color="blue">accounting</font> principles are as     follows:       ·       Revenue <font color="blue">recognition</font>;       ·       <font color="blue">Accounting </font>for share-based payments;       ·       <font color="blue">Accounting </font>for income taxes; and       ·       <font color="blue">Accounting </font>for business <font color="blue">combination</font>s and related goodwill</td>
    </tr>
    <tr>
      <td>In  particular,  the FASB <font color="blue">recently issued</font> SFAS 123R which requires the     <font color="blue">measurement</font> of all share-based payments to employees, including grants of     employee stock options, using a fair-value-based method and the recording of     <font color="blue">such expense</font> in our <font color="blue">consolidated statements</font> of <font color="blue">operations</font></td>
    </tr>
    <tr>
      <td>The <font color="blue">accounting</font>     provisions of SFAS 123R are <font color="blue">effective</font> for <font color="blue">annual periods beginning</font> after     June 15, 2005</td>
    </tr>
    <tr>
      <td>We are required to adopt SFAS 123R in the <font color="blue">first quarter</font> of     fiscal year 2006</td>
    </tr>
    <tr>
      <td>We believe that the adoption of SFAS 123R will have a     <font color="blue">significant</font> adverse effect on our reported financial results and may impact     the  way in which we conduct our business</td>
    </tr>
    <tr>
      <td>Please refer to the section     entitled   &amp;quote Recent  <font color="blue">Accounting </font> Pronouncements &amp;quote  for further information     regarding SFAS 123R       We do not intend to <font color="blue">pay cash dividends on</font> our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>As a result, you     will not receive any <font color="blue">periodic income from</font> an <font color="blue">investment</font> in our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>We  have  never paid a <font color="blue">cash dividend on</font> our <font color="blue">common stock</font> and we do not     anticipate <font color="blue">paying cash dividends</font> in the <font color="blue">foreseeable future</font></td>
    </tr>
    <tr>
      <td>We intend to     retain  any  earnings  for use in the <font color="blue">development</font> and expansion of our     business</td>
    </tr>
    <tr>
      <td>In addition, applicable provisions of <font color="blue">Delaware </font>law and our debt     <font color="blue">instruments may affect</font> our ability to declare and <font color="blue">pay dividends on</font> our     <font color="blue">common stock</font> and our <font color="blue">preferred stock</font></td>
    </tr>
    <tr>
      <td>Accordingly, you should not expect to     receive any <font color="blue">periodic income from</font> owning our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>Any <font color="blue">economic gain</font>     on your <font color="blue">investment</font> will be <font color="blue">solely from</font> an <font color="blue">appreciation</font>, if any, in the price     of the stock</td>
    </tr>
    <tr>
      <td>Anti-takeover  provisions  could  impede  or  discourage a third-party     <font color="blue">acquisition</font> of our company</td>
    </tr>
    <tr>
      <td>This could prevent <font color="blue">stockholders</font> from receiving a     <font color="blue">premium over market price</font> for their stock</td>
    </tr>
    <tr>
      <td>We are a <font color="blue">Delaware </font><font color="blue">corporation</font></td>
    </tr>
    <tr>
      <td>Anti-takeover provisions of <font color="blue">Delaware </font>law     <font color="blue">impose various obstacles</font> to the ability of a <font color="blue">third party</font> to acquire control     of our company, even if a change in <font color="blue">control would</font> be <font color="blue">beneficial</font> to our     existing <font color="blue">stockholders</font></td>
    </tr>
    <tr>
      <td>In addition, our <font color="blue">Board of Directors </font>has adopted a     <font color="blue">stockholder rights</font> plan and has designated a series of <font color="blue">preferred stock</font> that     could be <font color="blue">used defensively</font> if a takeover is threatened</td>
    </tr>
    <tr>
      <td>Our <font color="blue">in<font color="blue">corporation</font></font>     under <font color="blue">Delaware </font>law, our <font color="blue">stockholder rights</font> plan, and our ability to issue     <font color="blue">additional</font> series of <font color="blue">preferred stock</font>, could impede a merger, takeover or     other business <font color="blue">combination</font> involving our company or discourage a potential     <font color="blue">acquiror from</font> making a <font color="blue">tender offer</font> for our <font color="blue">common stock</font></td>
    </tr>
    <tr>
      <td>This <font color="blue">could reduce</font>     the <font color="blue">market value</font> of our <font color="blue">common stock</font> if investors view these <font color="blue">factors as</font>     preventing <font color="blue">stockholders</font> from receiving a premium for their shares</td>
    </tr>
    <tr>
      <td>We are exposed to <font color="blue">market risk from foreign currency exchange rates</font></td>
    </tr>
    <tr>
      <td>With two operating <font color="blue">subsidiaries</font> and <font color="blue">third party</font> <font color="blue">manufacture</font>rs in Europe,     economic  and  political <font color="blue">development</font>s in the <font color="blue">European Union </font>can have a     <font color="blue">significant</font>  <font color="blue">impact on</font> our business</td>
    </tr>
    <tr>
      <td>All of our products are currently     <font color="blue"><font color="blue">manufacture</font>d</font> in Europe</td>
    </tr>
    <tr>
      <td>We are exposed to <font color="blue">currency fluctuations</font> related to     payment for the <font color="blue">manufacture</font> of our products in Euros and other currencies     and <font color="blue">selling them</font> in US dollars and other currencies</td>
    </tr>
  </tbody>
</table>